Atezolizumab Plus Chemo Improves PFS in Frontline, Advanced/Recurrent Endometrial Cancer
October 21st 2023The addition of atezolizumab to chemotherapy improved progression-free survival in frontline advanced or recurrent endometrial carcinoma, in particular, among patients with deficient mismatch repair status.
Read More
Modest Activity With Sacituzumab Govitecan in Pretreated HNSCC
October 21st 2023Modest but durable antitumor activity was observed with sacituzumab govitecan-hziy in the treatment of patients with metastatic or locally recurrent head and neck squamous cell carcinoma who received between 1 and 3 prior lines of therapy.
Read More
Pembrolizumab/Chemoradiotherapy Shows Clinically Meaningful PFS Improvement in Cervical Cancer
October 20th 2023Data from the KEYNOTE-A18 trial support the addition of pembrolizumab to chemoradiotherapy, which has been in place as standard of care for patients with newly diagnosed, previously untreated, high-risk locally advanced cervical breast cancer since 1999.
Read More
KEYNOTE-811 Trial of Pembrolizumab Combo Improves PFS in HER2+ Gastric/GEJ Cancer
October 20th 2023The addition of pembrolizumab to trastuzumab plus chemotherapy improved progression-free survival in the first-line for patients with metastatic HER2-positive gastric or gastroesophageal junction cancer.
Read More
Improved pCR in Gastric/GEJ Cancer with Durvalumab/Chemo
October 20th 2023The addition of durvalumab to standard-of-care chemotherapy shows potential to improve downstaging in patients with resectable gastroesophageal junction and gastric cancer, according to findings from the phase 3 MATTERHORN study.
Read More
Adagrasib/Pembrolizumab Promising in KRAS G12C-Mutated NSCLC
October 20th 2023Longer follow-up data from the KRYSTAL-7 trial support the initiation of a phase 3 trial evaluating concurrent adagrasib with pembrolizumab in treatment-naïve patients with KRASG12C-mutated non–small cell lung cancer and PD-L1 ≥50%.
Read More
Improved PFS in Advanced Ovarian Cancer With Senaparib vs Placebo
October 20th 2023The phase 3 FLAMES trial results demonstrated an improvement in progression-free survival with senaparib monotherapy vs placebo, regardless of patient subgroup, in patients with newly diagnosed, advanced ovarian cancer.
Read More
Adjuvant Abemaciclib/ET Shows Sustainable Efficacy in HR+, HER2- Early Breast Cancer
October 20th 2023Extending abemaciclib with endocrine therapy for 2 years continues to lower the risk of invasive disease and distant relapse in hormone receptor-positive, HER2-negative breast cancer, as demonstrated in the 5-year efficacy findings from the monarchE trial.
Read More
Forimtamig Shows Deep, Durable Responses in Relapsed/Refractory Multiple Myeloma
September 29th 2023At a median duration of response of 12.2 months, the objective response rates with forimtamig across all dose levels was 66.7% with a very good partial response rate of 54.2%, according to data from a phase 1a dose-escalation trial.
Read More
Real-World Study of Teclistamab Matches MajesTec-1 Efficacy Data in RRMM
September 29th 2023According to data presented at IMS 2023, a real-world analysis showed that teclistamab demonstrated comparable efficacy to the results observed in the phase 2 MajesTec-1 trial for patients with relapsed/refractory multiple myeloma.
Read More
Safety/Efficacy of Dara-KRd and Double Transplant Confirmed in Newly Diagnosed Myeloma
September 29th 2023The Dara-KRd regimen with double transplant induced deep response rates and a high minimal residual disease negativity rates among patients with high-risk, newly diagnosed multiple myeloma.
Read More
CAR T Cells and Bispecifics Generate Excitement in Multiple Myeloma
September 29th 2023Madhav V. Dhodapkar, MBBS, discusses some of the immunotherapies under investigation and those that are being highlighted at the 20th International Myeloma Society Annual Meeting for patients with multiple myeloma.
Watch